This concerns combination dosing theory for rigosertib and azacitidine in the treatment of higher-risk myelodysplastic syndrome, within the domain of hematologic oncology pharmacology. The governing principle is pharmacodynamic sequencing: preclinical evidence demonstrated synergistic action between the two agents in vitro specifically when rigosertib is administered prior to azacitidine, which informed a sequential combination dosing schedule rather than simultaneous co-administration. This exemplifies the broader pharmacologic concept of drug-sequencing dependency in combination-therapy regimens, where the temporal order of administration—not merely the presence of both agents—determines therapeutic synergy.
This concerns combination dosing theory for rigosertib and azacitidine in the treatment of higher-risk myelodysplastic syndrome, within the domain of hematologic oncology pharmacology. The governing …